{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:12:32Z","timestamp":1789999952564,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.clml.2011.04.005","type":"journal-article","created":{"date-parts":[[2011,5,20]],"date-time":"2011-05-20T23:49:57Z","timestamp":1305935397000},"page":"379-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature"],"prefix":"10.1016","volume":"11","author":[{"given":"Ajay","family":"Nooka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pareen J.","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.04.005_bib1","first-page":"393","article-title":"Improving outcomes for patients with diffuse large B-cell lymphoma","volume":"60","author":"Flowers","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2011.04.005_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.25765","article-title":"Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States","volume":"117","author":"Shenoy","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.04.005_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2334-10-97","article-title":"Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups","volume":"10","author":"Faustini","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clml.2011.04.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.20205","article-title":"B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review","volume":"111","author":"Negri","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2011.04.005_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12185-008-0175-3","article-title":"Prevalence of hepatitis B and C viruses in patients with lymphoproliferative disorders","volume":"88","author":"Okan","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2011.04.005_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","article-title":"Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium","volume":"6","author":"de Sanjose","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2011.04.005_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3892\/ijo_00000618","article-title":"Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia?","volume":"36","author":"Libra","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clml.2011.04.005_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/ajcp\/109.5.600","article-title":"Extranodal lymphomas associated with hepatitis C virus infection","volume":"109","author":"Ascoli","year":"1998","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2011.04.005_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0609.2008.01081.x","article-title":"Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma","volume":"81","author":"De Renzo","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.04.005_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/10428190701732861","article-title":"Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma","volume":"49","author":"Park","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.04.005_bib11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2005.01.5016","article-title":"Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs","volume":"24","author":"Besson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.005_bib12","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","article-title":"Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies","volume":"15","author":"Dal Maso","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clml.2011.04.005_bib13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-128-7-199804010-00027","article-title":"Hepatitis C virus genotype distribution in B-cell non-Hodgkin lymphoma","volume":"128","author":"Luppi","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2011.04.005_bib14","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/jcm.32.4.884-892.1994","article-title":"Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey","volume":"32","author":"McOmish","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clml.2011.04.005_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/1042819031000076972","article-title":"Hepatitis C virus (HCV) and lymphomagenesis","volume":"44","author":"Weng","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.04.005_bib16","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood.V97.6.1555.h8001555_1555_1559","article-title":"The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection","volume":"97","author":"Zuckerman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.005_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clim.2010.02.002","article-title":"Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients","volume":"135","author":"Ito","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clml.2011.04.005_bib18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(96)90991-5","article-title":"HCV and non-Hodgkin lymphoma","volume":"347","author":"Hanley","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.04.005_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0168-8278(92)90073-X","article-title":"Infection of peripheral mononuclear blood cells by hepatitis C virus","volume":"15","author":"Zignego","year":"1992","journal-title":"J Hepatol"},{"key":"10.1016\/j.clml.2011.04.005_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.005_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2008.07565.x","article-title":"Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas","volume":"145","author":"Mazzaro","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.04.005_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.005_bib23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.22106","article-title":"A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial","volume":"47","author":"Hsu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2011.04.005_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ajh.21343","article-title":"Incidence of hepatitis B reactivation following rituximab therapy","volume":"84","author":"Hanbali","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.04.005_bib25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3324\/haematol.2009.005819","article-title":"Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance","volume":"94","author":"Ziakas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.04.005_bib26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.21783","article-title":"Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model","volume":"46","author":"Saab","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2011.04.005_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMoa013376","article-title":"Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection","volume":"347","author":"Hermine","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.04.005_bib28","first-page":"343","article-title":"Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy","volume":"29","author":"Mazzaro","year":"1997","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2011.04.005_bib29","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2604::AID-CNCR26>3.0.CO;2-V","article-title":"Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy","volume":"77","author":"Mazzaro","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.04.005_bib30","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJM200212263472614","article-title":"Regression of splenic lymphoma after treatment of hepatitis C virus infection","volume":"347","author":"Mazzaro","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.04.005_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.21022","article-title":"Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy","volume":"83","author":"Ennishi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.04.005_bib32","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2007.15.4807","article-title":"Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma","volume":"26","author":"Hsieh","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.04.005_bib33","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","article-title":"Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis","volume":"116","author":"Ennishi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.005_bib34","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1182\/blood-2010-09-307827","article-title":"Hepatitis C in the rituximab era","volume":"116","author":"Foran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.04.005_bib35","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","article-title":"Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy","volume":"17","author":"Visco","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2011.04.005_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(96)90212-3","article-title":"Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus","volume":"347","author":"Vento","year":"1996","journal-title":"Lancet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011000541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:27Z","timestamp":1761870087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S2152265011000541"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.04.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}